ALRN 6924

Drug Profile

ALRN 6924

Alternative Names: ALRN-6924

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aileron Therapeutics; Roche
  • Developer Aileron Therapeutics
  • Class Antineoplastics; Peptides
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haematological malignancies; Solid tumours
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 11 Apr 2018 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia released by Aileron Therapeutics
  • 04 Apr 2018 Interim efficacy data from a phase I/Ib trial in Acute myeloid leukaemia and Myelodysplastic syndromes released by Aileron Therapeutics
  • 02 Apr 2018 Interim efficacy data from a phase I trial in Solid tumours and Haematological malignancies released by Aileron Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top